Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 73 out of 100. Laboratory science

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Triggering receptor expressed on myeloid cells 2 (TREM2) regulates microglial function and is implicated in Alzheimer's disease (AD) pathogenesis. Here we conducted a phase 2, randomized, double-blind, placebo-controlled trial of a humanized TREM2 agonistic monoclonal antibody in 381 participants with early AD. Participants were randomized (1:1:1:1) to receive AL002 (15 mg kg -1 , 40 mg kg -1 or 60 mg kg -1 ) or placebo intravenously every 4 weeks for 48-96 weeks. AL002 demonstrated sustained target engagement and pharmacodynamic responses in the central nervous system, as demonstrated by reductions in soluble TREM2 and increases in osteopontin in cerebrospinal fluid, respectively. The study did not meet the primary endpoint of change from baseline in the Clinical Dementia Rating-Sum of Boxes score (versus placebo) (least squares mean difference versus placebo (95% confidence interval) at week 96: 15 mg kg -1 -0.31 (-1.61 to 0.98), 40 mg kg -1 0.13 (-1.18 to 1.43) and 60 mg kg -1 -0.17 (-1.49 to 1.15); P > 0.05 from mixed-effects model for repeated measures). The most frequent treatment-emergent adverse events were magnetic resonance imaging changes resembling amyloid-related imaging abnormalities (ARIA). This first trial of a TREM2 agonistic antibody in early AD was negative but provides findings relevant to the study of TREM2 therapeutics and ARIA. ClinicalTrials.gov: NCT04592874 .

What this study adds

Evidence grade: Null result

The record lists 381 participants. The most frequent treatment-emergent adverse events were MRI changes resembling amyloid-related imaging abnormalities, so this treatment was negative for clinical benefit in this trial.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mummery, C. J., Mayorga, A. J., Simmons, A., Chow, T. W., Burgess, B., Nguyen, T., et al. (2026). The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04273-1

Vancouver

Mummery CJ, Mayorga AJ, Simmons A, Chow TW, Burgess B, Nguyen T, et al. The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nature Medicine. 2026. doi:10.1038/s41591-026-04273-1. PMID: 41787076.

BibTeX

@article{mummery2026-41787076,
  author  = {Mummery, C. J. and Mayorga, A. J. and Simmons, A. and Chow, T. W. and Burgess, B. and Nguyen, T. and Gao, J. and Budda, B. and Park, L. Q. and Gupta, R. and Li, C. and Shi, L. and others},
  title   = {{The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial}},
  journal = {Nature Medicine},
  year    = {2026},
  doi     = {10.1038/s41591-026-04273-1},
  pmid    = {41787076},
  url     = {https://doi.org/10.1038/s41591-026-04273-1}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this phase 2 trial of 381 participants with early Alzheimer's disease, the TREM2 agonistic antibody AL002 did not meet the primary endpoint of change in the Clinical Dementia Rating-Sum of Boxes score versus placebo, although it showed target engagement in the central nervous system. The most frequent treatment-emergent adverse events were MRI changes resembling amyloid-related imaging abnormalities, so this treatment was negative for clinical benefit in this trial.

Study details

How this study scored 73/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 8 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 2 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 6 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 72 of the 98 points it could be judged on, which is 73 of 100. Total 73 of 100.72 of the 98 points we could judge = 73 of 100

Published in a top-tier journal, and it is a mid-stage phase 2 trial. We have no data on free to read, so that was left out: it earned 72 of the 98 points we could judge it on, which is 73 out of 100.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Nature Medicine)
Journal's citation record 4 / 4 Nature Medicine: journal h-index 763 (OpenAlex, 2026-10-29)
Study design 8 / 12 A mid-stage phase 2 trial
Strength of evidence 3 / 5 Rated “null-result” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 2 / 4 381 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 3 / 7 Cited 31 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 15.5 citations a year over 2 year(s) since 2026
Impact for its field and year 6 / 6 Cited 128.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 31 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Giacomo Salvadore: h-index 29 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41787076)
Free to read — / 2 Access not recorded — left out of this score
Points 72 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 72 of the 98 points we could judge it on is 73 out of 100.
Total 73 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 33.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Laboratory science from nearby years

Also tagged “r47h”

363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Laboratory science

See all studies in Laboratory science →